After establishing itself as one of Europe’s largest probiotic health companies, Kijimea entered the U.S. market in early 2026 — starting with a portfolio of three of its key probiotic products.

United States, October 28, 2026 -- Kijimea, Inc. is one of Europe's largest and fastest-growing probiotic companies. It has announced a bigger commitment to gut health in the United States, backed by rigorous science. Kijimea entered the U.S. market in early 2026 and brings the same scientific standards and German precision that made it successful in Europe. Strong demand from American consumers shows that interest in science-based gut health options is growing. As shoppers grow more skeptical of a crowded supplement market, Kijimea is doubling down on what it has always stood for: science first.

The announcement reflects Kijimea’s long-term vision to help establish gut health as a cornerstone of lasting wellbeing and to advance probiotics as a science-based foundation for a longer, healthier life. Rather than following trends, the company develops its products from the research up, with an in-house R&D team and a broad network of internationally recognized scientists and universities.

Separating science from hype

Probiotic research is still in its early stages. The microbiome is linked to immunity, metabolism, mental health, and hormone balance, but much of how these connections work is still not fully understood. At the same time, consumers are flooded with products that all claim to be the answer. That makes one question more important than ever: who can they trust?

“Walk into any pharmacy or browse online, and suddenly every product claims to be the answer,” said David Rietbrock, CEO of Kijimea. “Consumers are overwhelmed and often misled. When people ask whether a product is legit, they’re really asking a broader question: who can I trust with my health? We take that responsibility very seriously.”

That trust, the company says, is earned through evidence and transparency rather than buzzwords. Kijimea conducts its own gold-standard clinical studies — randomized, double-blind and placebo-controlled — instead of relying solely on general probiotic literature. One prominent example: A study with 443 participants, published in The Lancet Gastroenterology & Hepatology, examined the efficacy of the company’s patented strain B. bifidum HI-MIMBb75 across key gastrointestinal symptoms. More recently, Kijimea partnered with Germany’s renowned Charité on a clinical study exploring the role of probiotics in allergy relief, with results published in the peer-reviewed journal Allergy.

A focused, research-led portfolio

Kijimea’s portfolio centers on a small number of carefully developed products rather than a broad catalog. Its bestsellers include 1) Kijimea K53, a multi-strain formulation for a diverse microbiome, 2) Kijimea PRO, built around the clinically studied strain B. bifidum HI-MIMBb75 to reduce occasional bloating, constipation, and diarrhea and 3) Kijimea Women, built to support vaginal health. Across the range, the company’s emphasis remains the same: ingredient choices grounded in research and communicated transparently.

Looking ahead

“We believe gut health will play a major role in the future of medicine,” Rietbrock added. “The research emerging from universities and medical institutions worldwide is incredibly exciting, and consumers are smarter and more informed than ever. Companies now have to earn trust instead of buying attention. We’d rather underpromise and build credibility for the long term.”

With this renewed commitment, Kijimea intends to continue investing in clinical research, scientific collaboration and responsible consumer education as it expands internationally.

About Kijimea

Kijimea is a probiotic health company known in Europe for its research-driven approach to gut health. The company develops its products in-house and underpins them with its own gold-standard clinical studies — including research published in journals such as The Lancet Gastroenterology & Hepatology and Allergy — alongside collaborations with leading institutions such as the Charité. Its mission is to advance awareness of gut health and microbiome science responsibly, and to help establish probiotics as a science-based foundation for long-term wellbeing.

References

1. Andresen V, et al. Heat-inactivated B. bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS. The Lancet Gastroenterology & Hepatology. 2020;5(7):658-666.

2. Clinical study on probiotics in allergy relief, conducted in cooperation with Charité – Universitätsmedizin Berlin; results published in Allergy (peer-reviewed).

3. “Gut health supplements: Separating myths from facts.” Sponsored content, USA TODAY, September 2026.

These statements have not been evaluated by the Food & Drug Administration (FDA). These products are not intended to diagnose, treat, cure or prevent any disease. Individual results may vary.

This content is sponsored advertising content and is for informational purposes only; it does not constitute medical advice. If you have, expect to have, or suspect you may have any medical condition, consult a qualified healthcare provider.

Contact Info:
Name: David Rietbrock
Email: Send Email
Organization: Kijimea, Inc.
Address: 120 Wall Street, 10005 New York
Website: https://www.kijimea.com

Release ID: 89207686

In case of identifying any errors, concerns, or inconsistencies within the content shared in this press release that necessitate action or if you require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team is committed to addressing your concerns within 8 hours by taking necessary actions diligently to rectify any identified issues or supporting you with the removal process. Delivering accurate and reliable information remains our top priority.